Olsen et al., 1984, USA33 Olsen EA, Delzell E, Jegasothy BV. Second malignancies in cutaneous T cell lymphoma. J Am Acad Dermatol. 1984;10:197-204.
|
CTCL (n = 63) |
10 (15.9) |
Colon cancer (n = 2) |
Bladder cancer (n = 1), prostate cancer (n = 1), pyriform sinus carcinoma (n = 1), thymus germinoma (n = 1), bronchus carcinoma (n = 1), kidney cancer (n = 1), uterus cancer (n = 1), breast cancer (n = 1) |
Absent |
Kantor et al., 1989, USA44 Kantor AF, Curtis RE, Vonderheid EC, van Scott EJ, Fraumeni JF Jr. Risk of second malignancy after cutaneous T-cell lymphoma. Cancer. 1989;63:1612-5.
|
CTCL (n = 544) |
35 (6) |
Colon cancer (n = 7) |
Digestive system cancer (n = 11), respiratory system cancer (n = 11), breast cancer (n = 3), hematologic malignancies (n = 6), others (n = 4) |
17.1 |
Scarisbrick et al., 1999, England55 Scarisbrick JJ, Child FJ, Evans AV, Fraser-Andrews EA, Spittle M, Russell-Jones R. Secondary malignant neoplasms in 71 patients with Sézary syndrome. Arch Dermatol. 1999;135:1381-
|
SS (n = 71) |
9 (12.7) |
Lung cancer (n = 2) |
Endometrium cancer (n = 1), ovarian cancer (n = 1), pancreatic cancer (n = 1), HL (n = 1), prostate cancer (n = 1), bladder cancer (n = 1), unknown metastatic (n = 1) |
11.1 |
Väkevä et al., 2000, Finland66 Väkevä L, Pukkala E, Ranki A. Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma. J Invest Dermatol. 2000;115:62-5.
|
CTCL (n = 319) |
33 (10) |
Lung cancer (n = 12) |
Digestive system cancer (n = 5), breast cancer (n = 4), HL (n = 2), NHL (n = 2), genitourinary cancer (n = 2), leukemia (n = 2) |
18.2 |
Evans et al., 2004, United Kingdom77 Evans AV, Scarisbrick JJ, Child FJ, Acland KM, Whittaker SJ, Russell-Jones R. Cutaneous malignant melanoma in association with mycosis fungoides. J Am Acad Dermatol. 2004;50:701-5.
|
MF (n = 285) |
6 (2.1) |
Melanoma (n = 6) |
Not-included |
NA |
Huang et al., 2007, USA88 Huang KP, Weinstock MA, Clarke CA, McMillan A, Hoppe RT, Kim YH. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol. 2007;143:45-50.
|
MF & SS (n = 429) |
37 (8.62) |
HL and NHL (n = 7) |
Colon cancer (n = 5), lung cancer (n = 5), biliary system cancer (n = 2), melanoma (n = 1) |
18.9 |
Brownell et al., 2008, USA99 Brownell I, Etzel CJ, Yang DJ, Taylor SH, Duvic M. Increased malignancy risk in the cutaneous T-cell lymphoma patient population. Clin Lymphoma Myeloma. 2008;8:100-5.
|
CTCL (n = 672) |
37 (5.5) |
NHL (n = 7) |
Digestive system cancer (n = 3), respiratory system cancer (n = 4), melanoma (n = 2), HL (n = 2), AML (n = 3), CML (n = 1), multiple myeloma (n = 1), breast cancer (n = 1), prostate cancer (n = 5), female genital cancer (n = 4), urinary system cancer (n = 2), thyroid cancer (n = 1) |
37.8 |
Herro et al., 2009, USA1010 Herro E, DiCaudo DJ, Davis MDP, Weaver AL, Swanson DL. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol. 2009;61:271-5.
|
MF & SS (n = 533) |
23 (4.16) |
Systemic B-cell lymphomas (n = 23) |
Not-included |
NA |
Hodak et al., 2013, Israel1111 Hodak E, Lessin S, Friedland R, Freud T, David M, Pavlovsky L, et al. New insights into associated co-morbidities in patients with cutaneous T-cell lymphoma (mycosis fungoides). Acta Derm Venereol. 2013;93:451-5.
|
MF (n = 343) |
51 (15)
|
Breast cancer (n = 9) colon and rectal cancer (n = 23)
|
Hematologic malignancy (n = 16+10), breast cancer (n = 12+9), colon and rectal cancer (n = 23+4), prostate cancer (n = 17+9), lung cancer (n = 6+4), melanoma (n = 7+7), others (n = 7+8) |
18.2 |
MF (n = 683) |
88 (13)
|
Lindahl et al., 2014, Denmark1212 Lindahl LM, Fenger-Grøn M, Iversen L. Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: a Danish nationwide, population-based cohort study. J Am Acad Dermatol. 2014;71:529-35.
|
MF (n = 386) |
65 (15) |
Urinary tract and genitalia (n = 11) |
NHL (n = 8), other hematologic malignancies (n = 2), digestive (n = 10), colorectal cancer (n = 5), respiratory cancer (n = 10), melanoma (n = 1), breast cancer (n = 6) |
15.4 |
Amber et al., 2016, USA1313 Amber KT, Bloom R, Nouri K. Second primary malignancies in CTCL patients from 1992 to 2011: a SEER-based, population-based study evaluating time from CTCL diagnosis, age, sex, stage, and CD30+ subtype. Am J Clin Dermatol. 2016;17:71-7.
|
CTCL (n = 2923) |
183 (6) |
NHL (n = NA) |
HL, lung cancer and penile cancer (n = NA) |
NA |
Cengiz et al., 2017, Turkey1414 Cengiz FP, Emiroglu N, Onsun N. Frequency and risk factors for secondary malignancies in patients with mycosis fungoides. Turk J Hematol. 2017;34:378-9.
|
MF (n = 143) |
13 (9.1) |
HL (n = 3) |
NHL (n = 2), adult T-cell leukemia (n = 2), lung cancer (n = 2), renal cell cancer (n = 1), bladder cancer (n = 1), melanoma (n = 1) |
53.9 |
Kommalapati et al., 2018, USA1515 Kommalapati A, Tella SH, Go RS, Bennani NN, Goyal G. A population‐based analysis of second primary malignancies in T‐cell neoplasms. Br J Haematol. 2019;185:338-42.
|
MF & SS (n = 4774) |
472 (10) |
NHL and HL (n = NA) |
AML, thyroid cancer, prostate cancer, brain cancer, breast cancer, lung cancer (n = NA) |
NA |
Almukhtar et al., 2019, USA1616 Almukhtar R, Gill F, Soine R, McBurney E. Gender differences in the risk of secondary malignancies in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 2020;83:647-8.
|
MF & SS (n = 4229) |
550 (13) |
NHL (n = 98) |
Lung cancer (n = 82), CLL (n = 14), HL (n = 13), melanoma (n = 23) |
22.7 |
Goyal et al., 2020, USA1717 Goyal A, O'Leary D, Goyal K, Rubin N, Bohjanen K, Hordinsky M, et al. Increased risk of second primary malignancies in patients with mycosis fungoides: a single-center cohort study. J Am Acad Dermatol. 2020;82:736-8.
|
MF (n = 172) |
24 (14) |
Melanoma (n = 4) |
Anaplastic large cell lymphoma (n = 1), bladder cancer (n = 2), breast cancer (n = 2), CLL (n=1), cholangiocarcinoma (n=1), colon cancer (n = 1) endometrial cancer (1), HL (n = 1), NHL (n = 1) pancreatic cancer (n = 1), prostate cancer (n = 3), renal cancer (n = 3), tongue cancer (n = 1), uterine cancer (n = 1) |
12.5 |
Goyal et al., 2020, USA1818 Goyal A, O'Leary D, Goyal K, Rubin N, Bohjanen K, Hordinsky M, et al. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: a Surveillance, Epidemiology, and End Results analysis. J Am Acad Dermatol. 2020;83:404-411.
|
MF (n = 6742) |
511 (7.5) |
NHL (n = 50) |
HL (n = 3), leukemia (n = 7), multiple myeloma (n = 2), prostate cancer (n = 19), lung cancer (n = 12), colon cancer (n = 8) |
12.1 |
Goyal et al., 2021, USA1919 Goyal A, O’Leary D, Goyal K, Rubin N, Janakiram M. Screening for second malignancies in mycosis fungoides: non‐Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma. J Eur Acad Dermatol Venereol. 2021;35:1821-9.
|
MF (n = 7984) |
742 (9.29) |
NHL (n = 99) |
Melanoma (n = 25), HL (n = 14), lung cancer (n = 69), bladder cancer (n = 20) |
15.2 |
Liu et al., 2021, Canada2020 Liu YA, Finn AJ, Subtil A. Primary cutaneous lymphomas in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a series of 12 cases. J Cutan Pathol. 2021;48:617-24.
|
MF & SS (n = 5) |
5 (NA) |
CLL/SLL (n = 5) |
Not-included |
NA |
Scheu et al., 2021, Germany2121 Scheu A, Schnabl SM, Steiner DP, Fend F, Berneburg M, Yazdi AS. Importance of diagnostics and risk of secondary malignancies in primary cutaneous lymphomas. J Dtsch Dermatol Ges. 2021;19:373-81.
|
MF (n = 72) |
8 (11) |
Hematologic (n = 2) |
Solid tumors (n = 5), melanoma (n = 1) |
12.5 |
Błażewicz et al., 2021, Poland2222 Błażewicz I, Olszewska B, Stawczyk-Macieja M, Jaśkiewicz M, Nowicki RJ, Sokołowska-Wojdyło M. The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome. Postepy Dermatol Alergol. 2021;38:289-294.
|
MF & SS (n = 177) |
29 (16.4) |
Hematologic (n = 12) |
Lung cancer (n = 4), breast cancer (n = 2), bladder cancer (n = 2), kidney cancer (n = 2), melanoma (n = 2), others (n = 5) |
41.4 |
Pileri et al., 2021, Italy2323 Pileri A, Guglielmo A, Fuligni F, Lastrucci I, Patrizi A, Pimpinelli N, et al. Second neoplasm in cutaneous T-cell lymphoma patients: a marker of worse prognosis? Ital J Dermatol Venerol. 2021;156:484-488.
|
MF (n = NA) |
13 (NA) |
Lung cancer (n = 4) |
Prostate cancer (n = 2), pancreatic cancer (n = 2), others (n = 5) |
7.7 |
Present study, 2023, Turkey |
MF (n = 730) |
56 (7.1) |
Hematologic (n = 36) |
Breast cancer (n = 4), prostate cancer (n = 3), Kaposi’s sarcoma (n = 2), melanoma (n = 2), renal cell cancer (n = 2), thyroid cancer (n = 1), astrocytoma (n = 1), hepatocellular cancer (n = 1), endometrium cancer (n = 1), fibromyxoid sarcoma (n = 1), lung cancer (n = 1), gastric adenocarcinoma (n = 1) |
64.3 |